Compare Illumina, Inc. (ILMN) vs Sea Limited (SE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Illumina, Inc. vs Sea Limited — how do they compare? Illumina, Inc. trades at $191.6 (market cap $27.94B), while Sea Limited trades at $105.99 (market cap $64.73B). The key difference: Sea Limited is far larger — about 2.3× Illumina, Inc.'s market cap, and Illumina, Inc. is trading nearer its 52-week high, Sea Limited nearer its low. Which is the better fit depends on your goals.
| ILMN | SE | |
|---|---|---|
Market Cap | $27.94B | $64.73B |
Sector | Health | Media |
52-Week High | $194.33 | $196.50 |
52-Week Low | $91.00 | $78.16 |
Enterprise Value | $29.33B | $57.78B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Illumina (ILMN) trades at $185.36, down 0.69% on the day, with a bullish technical signal from moving averages. The stock shows strong profitability with a 19.42% net income margin and has beaten EPS estimates for three consecutive quarters. Recent news highlights expansion of the Billion Cell Atlas program and upcoming Q2 2026 earnings on July 30.
Outlook remains positive with 51% analyst buy ratings, though the current price exceeds the $178 consensus target. Key risks include competitive pressure from Roche's new sequencer and China market weakness. Earnings growth and cost control initiatives support upside potential, but valuation multiples suggest limited near-term appreciation.
Sea Limited (SE) trades at $106.00, up 1.87% on the day, with a bearish technical signal despite bullish moving averages. The company reported strong revenue growth, with 2025 revenue reaching $22.94 billion and net income of $1.58 billion, though recent quarterly earnings have been mixed. Positive cash flow trends and a robust analyst consensus with a $131.00 price target highlight fundamental strength, but insider selling and competitive pressures present headwinds.
The outlook for SE is cautiously optimistic, driven by sustained revenue expansion and improving profitability. Key risks include execution challenges in its e-commerce and gaming segments, geopolitical tensions affecting operations, and insider selling activity. The stock's valuation multiples suggest growth expectations are priced in, requiring continued strong performance to justify further upside.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Illumina, Inc.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Read more on ILMN →About Sea Limited
Sea Limited offers information technology services. The Company provides online personal computer and mobile digital content, e-commerce, and payment platforms. Sea serves customers worldwide.
Read more on SE →
